Please assess the completion status of the following clinical trial:

Trial Title: Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed ICF (Informed Consent Form)~2. Subject-reported history of Drye Eye Disease (DED) in both eyes~3. Ability and willingness to follow instructions, including participation in all study assessments and visits~Exclusion Criteria:~1. clinically significant slit lamp findings or abnormal lid anatomy at screening, including eye trauma, pterygium, active blepharitis, and active lid margin inflammation;~2. Stevens-Johnson syndrome or other severe systemic autoimmune diseases;~3. underwent LipiFlow procedure or intention pulsed light therapy within 6 months before baseline, or received Meibomian gland massage treatment within 2 weeks before baseline;~4. received or removed permanent lacrimal plug within 3 months before baseline;~5. DED secondary to scarring, radiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells;~6. ocular or periocular malignancy;~7. active ocular allergies, or allergy to the study drug or its components;~8. ongoing ocular or systemic infection;~9. use of contact lenses within 1 month before screening;~10. intraocular surgery or ocular laser surgery within 6 months before enrollment;~11. uncontrolled systemic disease or history of herpetic keratitis;~12. use of topical steroids, topical cyclosporine, lifitegrast, serum tears, or topical anti-glaucoma medication within 60 days before screening;~13. used any known oral drugs that could have caused eye dryness within 1 month before screening;~14. participated in or were participating in other clinical trials drugs or device within 60 days before baseline;~15. inappropriate to participate for other reasons judged by the investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group A: SHR8058 eye drops (Type: EXPERIMENTAL): None
- Treatment group B: saline eye drops (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).